Table 6. . Results of the CEA per surviving patient.

Study group	Total cost†	Mortality rate	Effectiveness (survival rate)	Incremental cost	Incremental effectiveness	ICER	Total cost per surviving patient‡
Apixaban	€2208	0.037	0.963	–	–	–	€2293
Acenocoumarol	€2482	0.083	0.917	-€274	0.046	-€5957	€2707

^†Total corrected cost including healthcare and non-healthcare costs.

^‡Estimated as the total cost divided by the effectiveness.

CEA: Cost–effectiveness analysis; ICER: Incremental cost–effectiveness ratio.